EHTH just reported Q1 2026 results after the close on May 6, and the setup heading into the print was more interesting than the stock's $1.97 price suggests.
The most compelling data point of recent weeks is not on the short side — it's inside the company. CEO Derrick Duke bought 187,969 shares at $1.38 in late February, a $259,000 purchase that registered a significance score of 3 out of 10. CFO John Dolan followed with a 25,000-share open-market buy at $1.53 in early March, worth roughly $38,000. Against a backdrop of near-universal insider selling elsewhere at the company — multiple executives ran small tax-related sells in April — those two open-market buys in the $1.30–$1.55 range stand out as the clearest expression of management conviction available in the data.
The Q1 release confirmed what those insiders may have seen coming: revenue of $88.0 million beat the $85.8 million consensus estimate, and full-year 2026 sales guidance of $405–445 million was affirmed, bracketing the $427.7 million street estimate. The EPS lines were messier — GAAP EPS of -$0.58 beat the -$0.68 estimate, though an adjusted figure of -$0.38 missed the -$0.28 consensus — keeping the bear case on profitability intact. Heading into tonight, the stock was already up 56% over the prior month to $1.97, so the market had been pricing in something better.
Positioning heading into the print told a loosening story. Short interest came into earnings at 5.7% of the free float — meaningful, but easing. It fell roughly 1.4% over the week and has now pulled back from a late-April spike that briefly pushed above 6%. Borrowing costs remain low at 0.54% annualised, and availability is extremely wide at over 2,300% of short interest, meaning the lending market is placing no constraint on new bearish positions. The ORTEX short score has drifted lower all week, from 44.7 on April 29 to 41.0 on May 5 — the trend runs against the shorts. Peer SLQT surged 52% on May 5 alone, adding noise to the sector read, but SelectQuote's move looked idiosyncratic rather than a broad insurance-broker re-rating.
The options market was equally unbothered. The put/call ratio fell to 0.03, well below its already-low 20-day average of 0.034, sitting near the 52-week floor of 0.024. That is about as bullish an options skew as this name ever shows — put demand had all but evaporated ahead of the results, suggesting traders with a view were expressing it through calls or simply staying away from the derivatives market altogether on a stock this thinly traded.
The analyst community has been under consistent downgrade pressure for months. RBC Capital cut its price target from $9.00 to $3.00 in March, maintaining a Sector Perform rating. Craig-Hallum downgraded to Hold in February after the previous quarter's brutal one-day drop of 31%. The mean analyst target of $2.25 sits close to the current price, but given RBC's $3.00 target was itself a two-thirds cut from prior levels, the consensus has little credibility as an anchor right now. Factor scores offer a partial offset: EPS momentum ranks in the 99th percentile on a 90-day basis and 85th percentile over 30 days, reflecting a run of upward estimate revisions — the same tailwind the insiders may have had visibility on.
The prior two earnings reactions were steep: -31% the next day after Q3 2025 results, and -24% after Q4 2025. Tonight's revenue beat and reaffirmed guidance break that pattern, at least on the top-line read. What the market focuses on next — profitability trajectory, LTV assumptions on Medicare Advantage renewals, or whether the Zacks upgrade on May 1 has any follow-through — will determine whether the five-week 56% rally has a second chapter or stalls into the details.
See the live data behind this article on ORTEX.
Open EHTH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
